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Ewing’s sarcoma is a highly malignant tumor that metastasizes rapidly and is thus associated with a low survival rate. The inten-
siﬁcation of chemotherapy has been shown to improve the overall survival of patients with Ewing’s sarcoma. However, intensiﬁed
chemotherapycanleadtoincreasedtoxicityoreventhedevelopmentofsecondarymalignancies.Thestratiﬁcationofpatientswith
Ewing’s sarcoma into “good” and “poor” responders may help guide the administration of progressively more intensiﬁed chemo-
therapy. Thus, an accurate assessment of the chemotherapeutic response, as well as the extent of chemotherapy-induced tumor
necrosis, is critical for avoiding potential treatment-related complications in these patients. This paper reviews the methods cur-
rently used to evaluate chemotherapeutic response in Ewing’s sarcoma, focusing speciﬁcally on histopathologic and imaging anal-
yses, and discusses novel therapies and imaging methods that may help improve the overall survival of these patients.
1.Introduction
The dramatic improvement in the survival of patients with
Ewing’s sarcoma during the past 2 decades can be attributed
to the use of aggressive chemotherapy. In the absence of
chemotherapy, this highly malignant tumor quickly metasta-
sizes, even when adequate local control has been achieved. In
patients without evidence of metastatic disease at presenta-
tion, treatment protocols for Ewing’s sarcoma incorporating
chemotherapy,surgery,andradiotherapyresultin5-yeardis-
ease-free survival rates of 40%–50% [1, 2]. The inclusion of
intensiﬁedchemotherapyimprovesthe2-yearevent-freesur-
vivalrateto77%[3].Thisﬁndingsuggeststhatfurtherinten-
siﬁcation of chemotherapy may improve local disease con-
trol; however, this can potentially lead to the onset of addi-
tional toxic eﬀects and even to the development of secondary
malignancies.
Deﬁning prognostic variables may ﬁnally permit the
stratiﬁcation of patients into “poor-risk” and “good-risk”
subgroups. This would allow the administration of progres-
sively more intensiﬁed therapy in the poor-risk subgroup,
decreasing the probability of choosing drug-resistant cellular
clones, with an increased risk of metastasis [4]. In the good-
risksubgroup,lessintenseandthereforepotentiallyless-toxic
therapy may be suﬃcient.
TheabilitytopredictthesurvivalofpatientswithEwing’s
sarcomaislimited,bothatthetimeofdiagnosisandafterini-
tialpreoperativechemotherapy.Clinicalsignsareinsuﬃcient
for determining the eﬀectiveness of preoperative chemother-
apy and are poorly correlated with histologic tumor response
[5]. The strongest predictor of outcome is the presence or
absence of metastatic disease [2, 3]. But this prognostic indi-
catorisnotusefulinmostpatientswithEwing’ssarcomawho
present with apparently localized disease. In these patients, 2
intrinsic factors and 1 treatment response factor have been
identiﬁed that predict outcome. Tumor size and genetic pro-
ﬁle are strong predictors of outcome. For example, tumors
with genetic alterations in p53 or p16/p14ARF have more2 Sarcoma
aggressive behavior and a worse response to chemotherapy
[6]. However, these prognostic factors are not under the
physician’s control. In contrast, the histologic response of the
primary tumor to preoperative chemotherapy is a powerful
predictor of the occurrence of relapse, which may be inﬂuen-
ced by the treatment team [7, 8].
In this paper, the methods designed to assess chemo-
therapy-induced tumor necrosis and how this parameter can
inﬂuence the prognosis and treatment of Ewing’s sarcoma
will be reviewed.
2. Histopathologic Assessment
Resection of the primary tumor is the best option for reduc-
ing the bulk of soft tissue tumors and has the potential to
eliminate tumor cells entirely from bone and soft tissue [9].
Thus, resection eliminates disease that could cause local re-
currence and further metastasis [10]. Although amputation
is appropriate for certain cases, limb preservation is possible
in most cases. Approximately 50% of Ewing’s sarcoma cases
overall, as well as 70% of extremity cases, are surgically re-
sectable. The histologic evaluation of resected specimens
allows the eﬀectiveness of preoperative chemotherapy to be
accurately evaluated [11, 12].
Essentially, 2 diﬀerent methods of histologic assessment
have been established. The ﬁrst, described by Huvos, is based
on his method for evaluating osteogenic sarcoma samples
[13]. In a semiquantitative manner, histologic evaluation is
performed by grading the extent of necrosis relative to the
percentage of residual viable tumor. The Huvos system in-
cludes 4 grades: Grade 1: little or no evidence of necrosis;
Grade 2: necrosis of 50%–90%; Grade 3: necrosis between
90%–99%; ﬁnally, Grade 4: 100% necrosis (Figure 1)[ 7].
This method of histologic grading has been shown to be
very eﬀective in the management of Ewing’s sarcoma. The
extent of necrosis has been directly correlated with improved
survival [7]. However, quantitative measurements are open
to criticism. Ewing’s sarcoma diﬀers from osteogenic sar-
coma in that it does not produce any major extracellular
matrix component, so there is no indicative evidence left
by the tumor cells. Furthermore, in response to chemother-
apy, Ewing’s sarcoma cells may disappear completely. For
these reasons, there may be a dramatic decrease in tumor
volume after preoperative chemotherapy without histologic
delineation of where the tumor was located originally [14].
Because of this potentially large change in tumor volume
following neoadjuvant chemotherapy, estimates of tumor
necrosis are diﬃcult to calculate based only on the viable
cells per unit area of residual tumor. Consequently, a strictly
quantitative method to estimate tumor necrosis may not
be appropriate in Ewing’s sarcoma [15]. However, because
pathologists are accustomed to using the well-established
Huvos system for osteogenic sarcoma, they are able to apply
it accurately to Ewing’s sarcoma.
Instead of estimating the amount of nonviable tumor,
Piccietal.[15]proposedevaluatingtheamountofremaining
viable tumor. They developed a method that requires cal-
culating the absolute quantity of viable tumor cells after
(a)
(b)
Figure 1: Fibrotic replacement of the marrow space occurred fol-
lowing chemotherapy. There were small foci of residual disease
grossly and histologically. Overall, systematic mapping of the resec-
tion specimen is essential to measure the response to preoperative
chemotherapy in the primary tumor (a). Anteroposterior view of
the specimen mapped into block segments (b). This response was
graded as good, with more than 90% necrosis (Grade 3, Huvos
system; Grade 2, Picci system).
preoperative chemotherapy, which does not vary with vol-
ume changes of the primary tumor. The scoring system
proposed by Picci et al. [15] includes 3 grades. Grade 1 res-
ponse represents a tumor with at least 1 macroscopic resi-
dualnoduleofviabletumor.Individualmacroscopicnodules
are deﬁned as those that are larger than one 10x magniﬁca-
tion ﬁeld, or as scattered microscopic nodules that indivi-
dually are smaller than one 10x magniﬁcation ﬁeld but that
collectivelyarelargerthanone10xmagniﬁcationﬁeld.Grade
2 response represents a tumor with only isolated microsco-
pic foci of viable tumor smaller than the size of a 10x magni-
ﬁcation ﬁeld. Grade 3 response indicates no evidence of via-
ble tumor cells [14]. This method is easy to interpret be-
cause it does not require the calculation of percentages, but
it does require an exhaustive examination of the tissue and
preparation of multiple sections [8]. Furthermore, this
method fails to account for the original tumor size. For ex-
ample,thepersistenceof1noduleisgradedthesame,regard-
less of whether the tumor volume was 10cm3 or 200cm3.
Akerm˚ an [16], who graded specimens of Ewing’s sar-
coma using the 2 scoring systems described above, showed
similar disease-free survival. Akerm˚ an stressed that the re-
gional mapping protocol was more important than the type
of grading system used (Figure 2). Picci et al. [15]s u p p o r t
this point by showing the signiﬁcance of this regional map-
ping of the tumor. They found that viable tumor was more
often detected in some of the preferential or sanctuary sites
than in the central part of the tumor. These preferential sites
were: (1) in the subperiosteal region of new bone formation,
(2) in the soft tissue mass, and (3) in areas of hemorrhage,Sarcoma 3
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Figure 2: Gross specimen and whole-mount sections demonstrat-
ing the areas of (a) necrosis and (b) residual disease.
present in 41% of patients. Furthermore, disease was present
in the intramedullary canal in 36% of patients.
Thus, an acceptable histologic response grading system
depends on a meticulous and precise macroscopic and mic-
roscopic examination of the surgical specimen. To accom-
plish this aim, it is very important to observe the following
steps. First, it isnecessarytoexamine thefreshspecimen very
soon after surgery. Second, it is crucial to keep multiple sec-
tions from the preferential sites. Third, it is imperative to cut
various sections from the area where the biopsy was obtain-
ed. Fourth, it is useful to saw the specimen into halves, using
one half for the multiple sections and the other half as a
whole tumor section. Fifth, the places where the cuts were
made must be represented in an illustration of the specimen
and kept as part of the permanent record.
3.ImagingAnalysis
Precise imaging methods have allowed the noninvasive iden-
tiﬁcation, localization, and quantiﬁcation of residual viable
tumor during and after preoperative chemotherapy in pa-
tientswithEwing’ssarcoma.Diagnosticimagingmayalsoin-
ﬂuence the adjustment of neoadjuvant chemotherapy sched-
ules or the timing of surgical intervention [11, 17]. However,
while estimates of tumor changes based on diagnostic imag-
ing studies are more reliable than those based on clinical
methods, they do not always predict histopathologic res-
ponse [12]. More reﬁned imaging techniques are needed to
monitortumorstatusduringtreatmentandtopredicttumor
response to treatment [18].
3.1. Conventional Radiography. Conventional radiography is
still useful for developing diﬀerential diagnoses, detecting
pathologic fractures, estimating tumor aggressiveness, and
during followup [19]. However, radiographs cannot be used
to accurately indicate the extent of medullar involvement or
to delineate soft tissue masses, unless the masses are heavily
calciﬁed.Inaddition,reductionsintumorsizemaybeunder-
estimated or overestimated on plain ﬁlm [11].
3.2. Radionuclide Studies. Semiquantitative analysis of tu-
mor activity can be achieved by means of radionuclides, be-
cause uptake of the labeled compound depends on cellular
function.
Static studies with methylene diphosphonate (MDP)
labeledwithtechnetium-99m (99mTc)are not usefulfor eval-
uating primary tumors because they often exaggerate the ex-
tentofthetumor.However,serialscintigramshavebeenused
to measure activity in the tumor, which is compared with
activity in normal contralateral bone. These dynamic studies
of 99mTc-MDP have been utilized to distinguish between
good responses and poor responses to chemotherapy [20].
Uptake of gallium-67 (67Ga)-citrate more closely deﬁnes
the actual tumor than that of 99mTc-MDP because 67Ga-
citrate is taken up quickly by Ewing’s sarcoma cells [21].
When ﬁndings on a bone scintigram with 99mTc-MDP re-
mainabnormalandnopathologicfractureispresent,normal
ﬁndings on a gallium study suggest that no residual malig-
nant disease is present [22].
Because of the rapid clearance from the blood and the
lack of accumulation in nonneoplastic bone of thallium-201
(201Tl), 201Tl scans appear to be more accurate than 67Ga-
citratescansorbonescanswith 99mTc-MDPinindicatingthe
course of disease. However, 201Tl scintigraphy has not been
widely used for this purpose [23, 24].
3.3. Computerized Tomography (CT). Computerized tomog-
raphy (CT) provides a cross-sectional view of sarcoma of
long bones. Its contrast resolution permits visualization of
the extraosseous soft tissue mass and involved bone marrow
[11]. However, in chemoresponsive tumors, CT changes in
the aﬀected bone marrow do not diﬀerentiate active tumor
from intramedullary necrosis [25]. The wide availability and
relative low cost of CT are attractive, but its sensitivity is
probably not suﬃcient, even when used with intravenous
contrast. CT may identify a persistent soft tissue mass after
induction chemotherapy. This correlates with a residual soft
tissue extension of tumor, incomplete response to chemo-
therapy, and diminished survival in these patients compared
withpatientswithoutpersistentdiseaseextensionbeyondthe
bony compartment [26].
4.MagneticResonance Imaging
4.1. Conventional Static Magnetic Resonance Imaging (MRI).
Eﬀorts to correlate modiﬁcations in static magnetic resonan-
ce (MR) signal intensity with therapeutic response have
yielded conﬂicting results. Discrimination of good and poor
responders by means of conventional static MR imag-
ing (MRI) is mainly based on subjectively interpreted
qualitative parameters [11, 27]. Moreover, marked overlap
has been reported between responders and nonresponders
using this technique [27]. For example, using static MRI,
Erlemann et al. [12]f o u n dad e c r e a s ei nt u m o rv o l u m e
after chemotherapy in 73% of responders and in 50% of4 Sarcoma
nonresponders, which means an accuracy of 61.9%. They
found that this decrease in tumor volume was not a signi-
ﬁcant indicator of response (P>. 05).
Some limitations in the use of conventional static MRI
havebeenobserved.Holscheretal.[27],onT2-weightedMR
images, found a complete concordance between changes in
the signal intensity of the extraosseous tumor component,
modiﬁcations in tumor volume, and histopathologic ﬁnd-
ings in 70% of patients. They concluded that changes in the
signal intensity of the extraosseous tumor component could
be indicative of a response to chemotherapy. However, no
correlation was found between changes in the intraosseous
tumor component and modiﬁcations in tumor volume or
histopathology.TheresultsofErlemannetal.[12]contradict
those of Holscher et al. [27], who found a correlation
between a decrease in T2-weighted signal intensity of the soft
tissue mass and a favorable histologic response after preoper-
ative chemotherapy. However, it is known that peritumoral,
or paratumoral, edema, which appears on T2-weighted MR
images as a border of high signal intensity surrounding the
tumor margins [28], may also decrease in response to
chemotherapy. Hence, these changes are not very speciﬁc.
TheinterpretationofsignalintensityonT2-weightedMR
images remains a problem. In general, low signal intensities
are related to acellular tissues, whereas high signal intensities
representthemorecellularpartsofthetumor[29].However,
MacVicar et al. [9] found microscopic clusters of viable cells
inareasofbothhigh-andlow-signalintensityaftertreatment
in 10 patients (70%). Moreover, they found patients that still
had microscopic tumor clusters even though all the soft
tissue tumors were so considerably reduced in size that
signal evaluation was impossible. This could be the reason
that Van Der Woude et al. [30] could not identify minimal
residualdisease(deﬁnedas<10%ofentiretumorvolume)in
specimensinwhichresidualfociofviablecellswereobserved
histologically. This means that MRI cannot exclude the pre-
sence of residual disease activity. So, although a pattern of
modiﬁcation in signal intensity is qualitative evidence of
a chemotherapeutic eﬀect, it is questionable for excluding
active disease [31].
4.2. Dynamic MRI. Dynamic MR studies with injection of
gadopentetate dimeglumine have been used to improve MR
images for assessing response to chemotherapy [12]. Dyna-
mic contrast-enhanced MRI is useful for detecting the most
viable parts of the tumor and serves as an initial pattern
for followup of the tumor treatment. Combined with histo-
pathologic assessment, dynamic imaging parameters are re-
commended for evaluating the eﬀect of neoadjuvant chemo-
therapy in patients with Ewing’s sarcoma [32]. Thus, dyna-
mic contrast-enhanced MRI correlates with percent necrosis
as determined by pathologists. This noninvasive method is a
useful tool for surgical planning [33].
In this technique, tumor signal intensity is drawn from
serial images obtained at 15- to 20-s intervals, and the
inclinationoftheresultanttime–intensitycurveiscalculated.
Diﬀerent patterns have been described.
Brisk slopes (>30%) represent higher perfusion or faster
uptake of the contrast agent, perhaps due to tumor
neovascularization. These proﬁles suggest the presence of
viable tumor [17, 34]. On dynamic MRI, tumor foci as small
as3–5mm2 canbedetected.Thesefociarenotanexceptional
ﬁnding in Ewing’s sarcoma after chemotherapy [35], and, as
Picci et al. [8] showed, they are also important for prognosis.
Nevertheless, dispersed or smaller-dimension nests of viable
tumor cells cannot be distinguished with dynamic contrast-
enhanced MRI. Furthermore, complete absence of early
enhancement does not exclude the presence of disseminated
viable cells [17].
Late and gradually enhancing or nonenhancing areas
correspond histopathologically to regions of chemotherapy-
induced necrosis, mucomyxoid degeneration, or ﬁbrosis.
Alternatively, this response is associated with reactive alter-
ations such as edema, hemorrhage, or osteomyelitis, or
with tumor-related extracellular matrices such as abundant
osteoid or chondroid.
EarlyandcontinuouslyampliﬁedstructuresseenonMRI
correspond to tumor-feeding arteries, growth plate vessels,
or remnant viable tumor at speciﬁc sites.
In general, responsive tumors show more gradual in-
creases of gadopentetate dimeglumine after preoperative
chemotherapy than do nonresponsive tumors. But retarded
uptake has been observed in necrotic areas, in cystic regions,
and in cartilaginous or myxomatous tissue [36].
Comparing the accuracy of diﬀerent imaging techniques
in evaluating the response to preoperative chemotherapy
in Ewing’s sarcoma, Erlemann et al. [12] assessed chemo-
therapeutic response with MRI, both with and without
gadolinium diethylene-triamine-pentaacetic acid (Gd-
DTPA) enhancement, and with dynamic Gd-DTPA studies,
and the results were compared with those of skeletal scinti-
graphy. Of all the techniques employed, dynamic MRI had
the highest degree of accuracy (85.7%) and was superior
to scintigraphy, particularly in patients who were receiving
intraarterial chemotherapy [12]. Compared with skeletal
scintigraphy, dynamic MRI has a clearly superior spatial
resolution, and areas of predilection for the persistence
of tumor cells can be examined directly. Compared with
angiography, which also has a high spatial resolution, dyna-
mic MRI is less invasive. Although this method has pro-
duced promising results, it requires relatively complex mani-
pulation of quantitative data and is currently unlikely to be
adopted as a routine radiologic practice [9].
Dynamic MRI does have some limitations, as it has
been observed to yield some false-positive results. The large
pathologic vessels in a zone of active subperiosteal new bone
formation, and the physeal vessels in young patients, occa-
sionally lead to overestimation of tumor extent, especially
towards the growth plate [17].
5. Tumor Vascularization Assessment
Because Ewing’s sarcoma commonly is an extremely vascular
tumor and because tumor neovascularization is associated
with prognosis and response to therapy in diﬀerent human
neoplasms [37], changes in tumor neovascularization can be
analyzed to evaluate the result of preoperative chemotherapySarcoma 5
[38, 39]. It has been reported that rapid disappearance of
tumorvesselsisrelatedtoafavorableresponsetochemother-
apy, while permanent pathologic vascularity implies a poor
response [40]. Several techniques have been designed for
assessing tumor vascularization.
5.1. Magnetic Resonance Angiography (MRA). Magnetic res-
onance angiography (MRA) permits the study of tumor neo-
vascularity in vivo [37]. This tumor characteristic appears
to correlate with tumor aggressiveness and the presence or
absence of metastases [38]. In patients who responded to
chemotherapy, MRA showed a marked reduction in tumor
neovascularity, whereas in patients who did not respond to
chemotherapy, MRA demonstrated persistent or increased
tumor neovascularity [37].
5.2.ColorDopplerFlowImaging(CDFI). ColorDopplerﬂow
imaging (CDFI) has also been used to estimate the response
to preoperative chemotherapy in patients with Ewing’s sar-
coma. Parameters used in this technique are related to the
modiﬁcation of blood ﬂow resistance. The disordered struc-
ture of the vascularity of viable tumor reduces the resistance
of the peripheral vascular bed. This is the main reason that
the peripheral resistance of tumor-feeding arteries is de-
creased or unaltered. Additionally, a persistent intratumoral
ﬂow is found. These 2 parameters suggest a poor histologic
response to chemotherapy in Ewing’s sarcoma [41]. In con-
trast, an increased resistive index is indicative of a good
response [39].
With CDFI it is possible to obtain qualitative as well as
quantitative parameters with spectral analysis. In this way,
estimation of qualitative anomalous ﬂow patterns within
tumors, and quantitative evaluation of tumor blood ﬂow
supply and intratumoral blood ﬂow have been performed
[42].
In monitoring the eﬀect of chemotherapy in Ewing’s
sarcoma, CDFI with spectral analysis has some advantages
over dynamic gadolinium-enhanced MRI and 3-phase bone
scintigraphy becauseofits claimedsuperioraccuracy,nonin-
vasive nature, accessibility, short duration examination, and
low cost [39, 42].
However, CDFI also has some disadvantages. It is tech-
nically diﬃcult to perform; its reproducibility needs to be
proven; it has poor spatial resolution; and it is not useful
for determining chemotherapeutic response in purely intra-
osseous tumors [42]. CDFI is also deﬁcient when there is a
concomitant healing fracture or a signiﬁcant hypoxic area
around the tumor [39].
6. Novel ImagingTechniques
PreliminaryresultsusingMRspectroscopyhavedemonstrat-
ed its ability to show some metabolic modiﬁcations in
chemoresponsive tumors. However, these results have not
been proven in the clinical setting. Positron emission tomo-
graphy (PET) is another imaging technique under consider-
ation for assessing the eﬀectiveness of neoadjuvant chemo-
therapy in Ewing’s sarcoma [11].
Imaging techniques such as CT or MRI cannot distin-
guish accurately between active and necrotic tumor cells.
Furthermore, these techniques are limited in their ability to
discriminateviabletumorcellsfromposttherapeuticchanges
or to exclude minimal residual disease [43, 44].
PET is increasingly being used as a diagnostic technique.
Because of the similarity between 2-[ﬂuorine-18]ﬂuoro-2-
deoxy-d-glucose (FDG) and glucose, PET can be used to
detect malignancies with glucose hypermetabolism [43, 45].
While conventional imaging modalities use morphologic
criteria to diﬀerentiate between benign and malignant tu-
mors, FDG PET utilizes an increased demand for glucose,
which is proportional to FDG uptake [44].
In several malignancies, PET can accurately predict path-
ologic changes, diﬀerentiate between local and disseminated
disease, evaluate the response to therapy, and detect relapsed
tumors [46, 47].
In patients with Ewing’s sarcoma, FDG PET correlates
with histologic response to neoadjuvant chemotherapy [5],
with a sensitivity and speciﬁcity of about 96% and 78%, res-
pectively [48].
However,PETcannotidentifythepreciseanatomiclocal-
ization of lesions because of its limited spatial resolution. But
the combination of PET with CT mitigates this limitation
[43].
In addition, PET/CT is more accurate than PET alone for
patients with Ewing’s tumors [43], because CT acquires the
anatomic data while PET obtains the metabolic information
[45].
7. Inﬂuence of Necrosis Assessment on
PrognosisandTreatment
7.1. Prognosis. The parameters obtained from the diﬀerent
methods of assessment described above have important im-
plications for prognosis. A strong correlation between prog-
nosis and tumor volume and necrosis has been observed in
patientstreatedwithpreoperativechemotherapyandsurgery
[8, 49]. When there is an increase in tumor size after chemo-
therapy, the histopathologic evaluation shows an inadequate
response, whereas when there is a decrease in tumor size,
the histopathologic evaluation shows a good response [30].
Thus, the inadequate response to chemotherapy in large tu-
morsisassociatedwiththepresenceordevelopmentofdrug-
resistant clones [5].
The risk of local recurrence and metastatic disease are
most strongly associated with the status of operative margins
[7]. In 1 study, an inadequate operative margin was the only
factor that inﬂuenced the risk of local recurrence [50]. An
important association between margin status and the eﬀec-
tiveness of preoperative chemotherapy has been reported by
other investigators [7] .T h ep r o b a b i l i t yo fl o c a lr e c u r r e n c eo f
Ewing’s sarcoma persists even in patients who have negative
resection margins, who have a good histologic response to
chemotherapy, and who receive local radiotherapy [51].
7.2. Treatment. The classiﬁcation of patients into good res-
ponders and poor responders through the careful assessment6 Sarcoma
ofnecrosismayencouragethedevelopmentofnewtreatment
strategies. In particular, poor responders would be treated
with more aggressive therapy.
Preoperative chemotherapy has become one of the cor-
nerstones in the treatment of patients with Ewing’s sar-
coma [18].Preoperativechemotherapyhassomeadvantages;
namely, it can be used to treat the disease early, diminishing
the likelihood of metastatic dissemination, or to reduce tu-
mor volume, permitting complete tumor resection without
the need for limb amputation.
Diﬀerent treatment protocols have been used in Ewing’s
sarcoma. In those patients without evidence of metastatic
diseaseatpresentation,thecombinedtreatmentwithchemo-
therapy,surgery,andradiotherapyproducesa5-yeardisease-
free survival rate of 40%–50% [1, 2].
The addition of ifosfamide and etoposide to the stan-
dard chemotherapy regimen of vincristine, dactinomycin,
cyclophosphamide, and doxorubicin (VACA + IE) has been
shown to improve survival. Since the incorporation of these
2 drugs, the disease-free survival rates have increased to bet-
ween 62% and 78% [2, 52–54]. In terms of histologic res-
ponse, these 2 agents have produced signiﬁcantly better
results, especially when ifosfamide is employed early in the
treatment [54].
Newtreatmentsusingalkylatingagents,atanevenhigher
dose intensity, have produced a 2-year event-free survival
rate of 77% [3]. Other investigators, however, have not
found an improvement in the outcome of patients using this
treatment approach [55]. Moreover, recent reports have re-
vealed a disturbing rate of secondary acute myelogenous
leukemiaalthough,asshownbyBaccietal.[56],thisincreas-
ed risk may be inﬂuenced by the use of concomitant radio-
therapy.
In terms of surgical technique, more precise histologic
and radiologic techniques have allowed better demarcation
ofthe operative margins andhave helped in the evaluation of
residual viable tumor at speciﬁc preferential sites. In patients
withapoorresponsetochemotherapy(Grade1or2),thereis
a greater probability of local recurrence than in those with a
goodresponsetochemotherapy(Grade3or4)(12.5%versus
4.5%) [7]. Eﬀorts to obtain wide surgical margins must be
intensiﬁed in these patients and greater consideration given
to adding postoperative radiotherapy, regardless of the ade-
quacy of the histologic margin.
Traditionally, the primary tumor has been treated with
deﬁnitive local therapy using radiotherapy [57]. Local con-
trol has been improved when patients receive doses greater
than 49Gy, when the tumors are 8cm or smaller, or when
patients receive doses greater than 54Gy for tumors larger
than 8cm [58].
Currently, most cases of Ewing’s sarcoma are treated by
limb salvage surgery combined with neoadjuvant chemo-
therapy,whichachievepatientsurvivalandpreservefunction
[59]. When an adequate surgical margin can be achieved
after preoperative chemotherapy, radiotherapy is not used.
Postoperative radiotherapy is reserved for cases in which
(1) the operative margin status was questionable or (2) the
response to chemotherapy was poor. Preoperative radiother-
apy is reserved for cases in which (1) the response to
chemotherapywaslimitedand(2)completesurgicalexcision
would not be possible or would require sacriﬁcing a critical
structure(s). Because of the necrosis and ﬁbrosis caused by
radiation, it is impossible to assess the response to chemo-
therapy if radiotherapy is administered preoperatively.
New therapies have been developed for those patients
in the high-risk subgroup. These new treatment protocols
useconventionalchemotherapyandconsolidationwithvery-
high-dose short-term chemotherapy containing busulfan
and melphalan, followed by autologous blood stem cells
[3, 60]. In certain groups of high-risk patients, consolidation
with myeloablative total-body irradiation and chemotherapy
followed by stem cell rescue might improve prognosis [61].
However, the available literature does not reveal a clear
advantage for consolidation with high-dose chemotherapy
[62].
Finally, other treatments like immunotherapy [63, 64]
and bisphosphonate therapy [65] have also been introduced
recently in Ewing’s sarcoma. Interferon (IFN) beta (IFN-β),
and to a lesser degree IFN alpha (IFN-α), inhibits Ewing’s
tumor cell proliferation. In a nude mouse model of Ewing’s
tumor xenografts, human-type IFN-α and (IFN-β), demon-
strated an antitumoral eﬀect. In addition, human IFNs en-
hance the antitumor eﬀect of ifosfamide. This combined
synergistic treatment induces a remarkable decrease in the
mitotic index and manifest necrosis [63]. Furthermore, this
treatmentprovokesthedownregulationofangiogenicfactors
such as vascular endothelial growth factor, matrix metal-
loproteinase-9, and urokinase plasminogen activator recep-
tor [64]. On the other hand, the bisphosphonate zoledronic
acid induces apoptosis and inhibits primary bone tumor
growth through a mechanism involving the upregulation of
osteoprotegerin in a primary Ewing’s sarcoma mouse model
[65].
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